Table 3.
Characteristics of studies which included other clinical populations.
| Authors | Region | Year published | Time of study | Design | Number | sex | Age, years | Population | Study quality (NIH) | Method of body composition evaluation | Sarcopenia indicator | Excessive weight indicator | Definition of SO | SO prevalence | Assessment of outcomes related to SO | Control group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mangus RS et al. (40) | USA | 2017 | 2002-2012 | CC | 81 | 35.8% male | ≤18 | Pediatric end-organ disease patients | 7 | CT | sarcopenic index= total psoas area/height2 | visceral fat index, subcutaneous fat index | lower sarcopenic index compared to controls, higher visceral fat and subcutaneous fat index compared to controls | NA | NA | yes, 1:1 age- and gender -matched |
| Mueske NM et al. (46) | USA | 2019 | 2011-2014 | P | 12 | 42% male | range: 10-21 mean: 14.4 | Pre-adolescents, AYA diagnosed with HR B-ALL or T-cell ALL | 9 | QCT, DXA | muscle volume/percent in the lower leg | BMI%≥85th according to Centers for Disease Control and Prevention before treatment initiation, increase of total body fat mass/fat percent during therapy | loss of muscle volume/muscle percent over time, increase of total body fat mass/fat percent over time | NA | NA | yes- age range matched |
| Joffe L et al. (49) | USA | 2020 | 2002-2017 | R | 39 | 53.8% female | range: 1.33-20 mean: 9.8 median:11 | Children, adolescents and young adults with solid tumors | 10 | CT | SM,RLT | BMI≥85th percentile for sex and age WHO and CDC increase of VAT during therapy | loss of SM and RLT over time, increase of VAT over time | NA | NA | no |
| Orgel E et al. (38) | USA | 2018 | NA | P | 50 | 60% male | range: 9.9-19.6 mean: 14.7 median:14.6 | Children and adolescents diagnosed with High-Risk B-Precursor ALL or T-cell ALL | 7 | DXA | Lean muscle mass | BMI≥85th percentile for sex and age according to CDC criteria before treatment initiation, increase of BF% during therapy | loss of lean muscle mass over time, increase of BF% over time | NA | NA | no |
ALL, acute lymphoblastic leukemia; AYA, adolescents and young adults; BF, body fat; BMI, body mass index; CC, case–control; CDC, Centers for Disease Control and Prevention; CT, computed tomography; DXA, dual-energy X-ray absorptiometry; NA, not available; P, prospective; QCT, quantitative computed tomography; R, retrospective; RLT, residual lean tissue; SM, skeletal muscle; VAT, visceral adipose tissue; WHO, World Health Organization.